Evidence map›Paper›PMID 41179328›Full record

ArticleCancer diagnosis & prognosis

Identification of Prognostic Gene Signatures for Survival of Patients With Phaeochromocytoma, Paraganglioma, and Other Tumor Types.

Ednah Ooko, Thomas Efferth

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ednah OokoLaboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
Thomas EfferthDepartment of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Tumor treatments remain unsatisfactory, as many patients continue to die despite therapy. There is an urgent need for novel drug targets, particularly for rare tumors. In this study, we sought to identify genes with prognostic significance for survival in patients with phaeochromocytoma or paraganglioma. We also examined whether these genes are relevant in other tumor entities. Patients and Methods: We mined the TCGA-based KM Plotter and studied 186 risk genes for phaeochromocytoma and paraganglioma. Results: Using Kaplan-Meier statistics, we performed 3,163 calculations based on 7,489 tumor biopsies and identified a 2-gene signature for phaeochromocytoma/paraganglioma (AQP4, FAM84H). Since the 186 risk genes are not exclusively related to the development of phaeochromocytoma/paraganglioma alone, we also investigated their prognostic relevance in 17 other tumor types. A clustered 12-gene signature has been found common in four other tumor entities (liver hepatocellular carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, lung adenocarcinoma). This signature consisted of Conclusion: Our analysis provides a basis for the development of a novel prognostic test to predict the survival time of patients.

Indexed as

Kaplan-Meier analysisparagangliomaphaeochromocytomaprognostic valuesurvival analysisThe Cancer Genome Atlas (TCGA)

Identifiers

PMID41179328
PMCPMC12577614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.